SAN FRANCISCO — OpenEvidence rode the wave of early enthusiasm for large language models by building a free chatbot for doctors. Physicians, especially trainees, have flocked to the platform to help make patient care decisions; the company claims that about 650,000 U.S. physicians use it actively.
In just four years, OpenEvidence has leveraged that popularity into a $12 billion valuation, going directly to clinicians and avoiding health tech’s traditional hospital procurement process. But the company is facing competitive pressures and questions about whether its ad-based business model can continue to propel the company forward.
At the STAT Breakthrough Summit West, OpenEvidence chief technology officer Zachary Ziegler said that while the company has grown by building for individual clinicians, it’s time to aim bigger.
